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Background/Aims: Estimated GFR (eGFR) is used extensively in epidemiological research. 
Validations of eGFR have demonstrated acceptable performance, but the dependence of 
creatinine and cystatin C on non-GFR factors could confound associations with disease. Few 
studies have investigated this issue in direct comparison with measured GFR (mGFR). We 
compared the associations between eGFR and mGFR and retinal vasculopathy, a marker of 
systemic microvasculopathy. 
Methods: Iohexol clearance and retinal photography were examined in the Renal Iohexol 
Clearance Survey in Tromsø 6 (RENIS-T6), which consists of a representative sample of 
middle-aged persons from the general population. A total of 1553 persons without self-
reported kidney disease, cardiovascular disease or diabetes were investigated. Three eGFR 
equations based on creatinine and/or cystatin C from the CKD-EPI-Collaboration were 
studied. Differences between eGFR and mGFR were analyzed with seemingly unrelated 
regression methods. 
Results: mGFR in the lowest quartile was associated with an increased multivariable-
adjusted odds ratio of retinopathy (OR 1.86, 95% confidence interval 1.16-2.97), but not with 
retinal artery or vein diameters. eGFRcys was consistently biased relative to mGFR in its 
associations with retinal vessel diameters across different models. eGFRcrea and eGFRcyscrea 
were also biased in several of these models (P<0.05). For retinopathy, the differences between 
the three eGFRs and mGFR were not statistically significant.  
Conclusions: Low mGFR is associated with retinopathy in the general population. eGFR 
based on creatinine and/or cystatin C are not valid substitutes for mGFR in studies of the 







The GFR is difficult and costly to measure accurately in epidemiological research. For this 
reason, equations have been developed to estimate the GFR using endogenous substances, 
primarily serum creatinine and cystatin C. These equations have been shown to have 
acceptable bias and precision relative to the measured GFR (mGFR). Estimated GFR (eGFR) 
is now being used as proxy for mGFR in most epidemiological studies of kidney function. 
 
Creatinine and cystatin C have been shown to be influenced by non-GFR factors [1-4]. 
Accordingly, the difference between mGFR and eGFR is not random measurement error but 
partly caused by factors that could also be correlated with disease. Estimates of disease risk 
based on eGFR could be biased even though the eGFR estimates themselves are unbiased. 
The difference observed between risk estimates associated with eGFR based on creatinine vs. 
cystatin C indicates that this is the case. It has been hypothesized that combining endogenous 
filtration markers with different non-GFR determinants in the same estimating equation could 
alleviate this problem. 
 
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on both 
creatinine and cystatin C is to date the best-validated estimating equation based on this 
principle [5]. However, although it has been found to have less bias and better precision than 
equations based on either substance alone, it is not known whether it is more similar to mGFR 
in its associations with clinical manifestations. Because the non-GFR determinants of 
creatinine and cystatin C differ, it is possible that they cancel out and that this equation is less 




We examined this issue in relation to the retinal microvasculature. Retinopathy and narrower 
retinal arteries and wider veins predict manifest cardiovascular disease (CVD) [6,7]. The 
vascular beds of the choroid and the glomeruli share several structural similarities, and 
important physiological mechanisms as the renin-angiotensin-aldosterone system are found in 
both the eye and the kidneys [8]. Accordingly, pathogens that affect the retinal 
microvasculature would also be expected to influence the glomeruli, as can be seen in e.g. 
diabetes and hypertension [9,10]. However, studies of the eGFR and retinal microvascular in 
the healthy general population have reached different results, which may partly be due to non-
GFR influences on creatinine and cystatin C. The Renal Iohexol-clearance Survey in Tromsø 
6 (RENIS-T6) has the largest population-based cohort with mGFR measured as iohexol 
clearance, which is accepted as an accurate method [11 ]. The cohort, which consists of a 
representative sample of the middle-aged general population without manifest CVD, diabetes 
or chronic kidney disease, has also been investigated with retinal photography. The aim of the 
present investigation was to compare the associations between retinal vasculopathy, mGFR 








The RENIS-T6 was an ancillary part of the sixth survey of the Tromsø Study, as previously 
described [12 ]. Those invited to the sixth survey (October 2007 to December 2008) included 
a 40% random sample of individuals aged 50 to 59 years drawn from the population registry 
and all individuals aged 60 to 62 years (5464 total subjects). Of these, 3564 subjects aged 50-
62 years completed the survey. We excluded 739 subjects with self-reported myocardial 
infarction, angina pectoris, stroke, diabetes mellitus or renal disease. The remaining 2825 
eligible subjects were invited to the RENIS-T6. Of the 2107 who responded, we excluded 12 
due to an allergy to contrast media, iodine or latex; 65 due to other reasons; and 48 who did 
not present for their appointments. A total of 1982 subjects remained for inclusion, and 1632 
were investigated according to a predefined target. Five participants were excluded due to 
technical failures in their GFR measurements, leaving 1627 included participants in the 
RENIS-T6 cohort (Figure 1). The cohort has been shown to be representative of all 2825 
eligible subjects [13]. 
 
For the present analyses, persons with a urinary albumin-creatinine ratio (ACR) >1.92 
mg/mmol for men or 2.83 mg/mmol for women [14] or diabetes (fasting serum glucose ≥7.0 
mmol/L or hemoglobinA1C ≥6.5%) were excluded [15]. 
 
A health questionnaire was administered. A family history of early myocardial infarction was 
defined as a first-degree relative with myocardial infarction before the age of 60 years. 
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Physical exercise was defined as leisure time activity leading to perspiration or 
breathlessness. 
 
This study was approved by the Norwegian Data Inspectorate and the Regional Committee 
for Medical and Health Research Ethics of North Norway. Written informed consent was 
obtained from all individual participants included in the study. All procedures performed 
were in accordance with the ethical standards of the institutional and/or national research 
committee and with the 1964 Helsinki declaration and its later amendments or comparable 
ethical standards. 
 
Retinal Vessel Diameters and Retinopathy 
Retinal photography was performed with a Visucam PRONM (Carl Zeiss Meditec, Jena, 
Germany) retinal camera. Computer-assisted measurements of the diameters of all vessels 
coursing through the area of one-half to one disc diameter from the optic disc margin were 
performed. Of each type, the six largest were summarized as the central retinal artery 
equivalent and the central retinal vein equivalent [16].  
 
Retinopathy grading was based on “The International Clinical Diabetic Retinopathy and 
Diabetic Macular Edema Disease Severity Scales”[17]. Microaneurysms, hemorrhages and 
cotton-wool spots were counted. The grade for the worse eye was used. For the counts of 
microaneurysms, hemorrhages and soft exudates, the sums of the counts for both eyes were 





The GFR was measured as the single-sample plasma clearance of iohexol, which has been 




The methods for measurements of conventional and ambulatory blood pressure (BP) have 
been described previously [22]. Fasting serum glucose, triglycerides, and LDL- and HDL-
cholesterol were measured using a Modular model P800 (Roche Diagnostics, GmbH, 
Mannheim, Germany). Hemoglobin A1C was measured with a liquid chromatographic method 
(Variant II instrument, Bio-Rad Laboratories, Hercules, CA, USA). Three consecutive 
samples of first-void spot urine were analyzed for albumin and creatinine as described 
previously [23]. The median ACR was used in the analyses.  
 
Creatinine was analyzed on the Hitachi Modular model using an enzymatic method (CREA 
Plus, Roche Diagnostics, GmbH, Mannheim, Germany). External quality assessment was 
provided by Labquality, Helsinki, Finland. The analysis at our laboratory was calibrated with 
serum X in the Nordic Reference Interval Project, which has been validated against isotope 
dilution mass spectroscopy [24]. The inter-assay coefficient of variation in the study period 
was 2.3%.  
 
Cystatin C was measured by particle-enhanced turbidimetric immunoassay using reagents 
from Gentian (Gentian, Moss, Norway) on a Modular E analyzer (Roche Diagnostics, GmbH, 
Mannheim, Germany). The inter-assay coefficient of variation in the study period was 3.1%. 
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External quality control was provided by Equalis (www.equalis.se). In 2013, 300 randomly 
selected samples frozen at  
-80ºC were reanalyzed with the same assay on a Cobas 8000 (Roche Diagnostics), and the 
baseline cystatin C values were recalculated to values standardized to the international 
reference ERM-DA471/IFCC [25]. Details are given in the online Supplemental Material. 
eGFR based on creatinine (eGFRcrea), on cystatin C (eGFRcys) and on both (eGFRcreacys) were 
calculated with equations developed by the CKD-EPI-Collaboration (Supplemental Table 1 in 
the online Supplemental Material) [5]. The performance of these equations in the RENIS-T6-
cohort with regard to bias, precision and accuracy has been reported previously [12,26]. 
 
Statistical Analyses 
Continuous variables are presented as the median (interquartile range). Differences across 
mGFR quartiles were tested with ANOVA or median, ordinal logistic, logistic or Poisson 
regression as appropriate. Tests for unadjusted linear and quadratic trends were performed 
using linear and squared terms for mGFR in the regressions. Serum triglyceride values were 
log transformed. 
 
Adjusted models of the retinal variables were analyzed with multiple linear or logistic 
regression using mGFR, eGFRcrea, eGFRcys or eGFRcreacys as the independent variable. Having 
a retinopathy grade greater than zero was analyzed as a dichotomous dependent variable in 
multiple logistic regression analyses. The central retinal artery and vein equivalents were 
analyzed in the same manner as the dependent continuous variables in multiple linear 




For each of the dependent variables above, separate multiple linear or logistic regression 
analyses were performed with mGFR, eGFRcrea, eGFRcys or eGFRcreacys as independent 
variables, both divided into equation-specific quartiles and used as continuous variables. In 
model 1, we adjusted for age, gender, body weight, height, body mass index, antihypertensive 
medication, lipid-lowering and non-steroidal anti-inflammatory drugs; and in model 2 for the 
same variables as in model 1 and, in addition,  history of first-degree relative with myocardial 
infarction before 60 years (yes/no), physical exercise (yes/no), daytime ambulatory MAP and 
PP, number of currently smoked cigarettes, LDL- and HDL-cholesterol, the log of fasting 
triglycerides and high-sensitivity C-reactive protein, urinary ACR and fasting glucose. 
Seemingly unrelated regression methods were used to test differences between the regression 
coefficients for the mGFR and the three eGFRs across the different regression models [27]. 
Body mass index was calculated as body weight divided by the square of height.  
 
Due to logistic problems, retinal examinations were not performed in some patients. Retinal 
vessel or retinopathy data were missing in 7.9 and 8.4% of the subjects, respectively. In 
compliance with current recommendations, missing data were imputed using multiple chained 
imputation in STATA/MP 12.1 (StataCorp LP, Texas, USA, www.stata.com). All statistical 
tests were performed on 50 imputed datasets using mi estimate in STATA. The imputation 
model has been described in detail in a previous publication [28]. 
 





Of the 1627 subjects in the cohort, persons with micro- or macroalbuminuria (n=44) or 
diabetes (n=33) were excluded. Three persons had both diabetes and microalbuminuria. 
Accordingly, 74 subjects were excluded, leaving 1553 for the present investigation (Figure 1). 
 
There were differences across the mGFR quartiles with regard to several characteristics 
(P<0.05) (Table 1). These findings have been discussed previously [1,22,29]. 
 
In unadjusted analyses, there were no associations between the retinal changes and mGFR 
quartiles (P≥0.05) (Table 2). Quadratic trends were not statistically significant for any of the 
retinal variables in Table 2. 
 
In both model 1 (adjusted for age, sex, medication and anthropometric measures) and 2 (fully 
adjusted), an mGFR in the lowest quartile was associated with an increased odds ratio (OR) 
for retinopathy (P<0.05)(Table 3). In model 2, the OR for retinopathy was 1.86 (95% 
confidence interval 1.16-2.97). The corresponding result for eGFRcreacys was similar at 1.63, 
but not statistically significant. The ORs for eGFRcrea and eGFRcys were even lower (Table 3). 
The results when mGFR and eGFR were analyzed as continuous variables were similar 
(Table 3). There were no statistically significant quadratic trends across the quartiles for 
mGFR or any of the eGFR. In all possible pairwise comparisons between the linear trend ORs 
for mGFR and the three eGFRs, there were no statistically significant differences between the 
estimates in any of the models (P>0.05). Seemingly unrelated regression methods were used 




eGFRcys was associated with both the central retinal artery and vein equivalents in both model 
1  and 2  in the multiple linear regression analyses (Table 4). Lower eGFRcys was associated 
with both wider retinal arteries and veins (P<0.05). eGFRcyscrea was associated with wider 
retinal veins in model 1 (P<0.05), but not in model 2. eGFRcrea in the lowest quartile was 
associated with narrower veins in model 1 (P<0.05), but not in model 2. There was no 
statistically significant quadratic trend across the quartiles for mGFR or any of the eGFR. 
 
When comparing all possible pairs of linear trend regression coefficients for mGFR and the 
three eGFRs in both models in Table 4 with seemingly unrelated regression methods, all the 
differences between mGFR and eGFRcys were statistically significant. Likewise, all the 
differences between mGFR and eGFRcyscrea were statistically significant except for retinal 
arteries in the fully adjusted model. There was no statistically significant difference between 
any of the estimates for mGFR and eGFRcrea in any of the models. When comparing all 
possible pairs of estimates for eGFRcrea, eGFRcys and eGFRcreacys, the differences were all 
statistically significant (Table 4). 
 
In a sensitivity analysis, all the analyses in tables 3 and 4 were repeated after exclusion of all 
subjects with mGFR, eGFRcrea, eGFRcys or eGFRcyscrea lower than 60 mL/min/1.73 m2. In the 
multiple logistic regression analyses of retinopathy, the results were similar to the original 
analyses (Supplemental Table 2). In the multiple linear regression analyses of the retinal 
vessels, the associations between lower eGFRcrea and both narrower arteries and veins were 
now statistically significant in both model 1 and 2 (Supplemental Table 3). The association 
between eGFRcys and wider arteries in the fully adjusted model 2 was no longer statistically 
significant. When comparing the estimates for mGFR and eGFRcrea, the differences were now 





We found an association between low mGFR and retinopathy in the general non-diabetic 
population, whereas there was no association between mGFR and retinal vessel diameters. If 
we had not measured GFR, but relied on one of the eGFR equations, the results would have 
been different. In particular, the use of eGFRcys would have given the result that there was no 
association with retinopathy, but a strong association with wider retinal vessels for lower 
eGFRcys. Statistical tests of the differences between the estimates of association across the 
GFR assessments demonstrated that none of the eGFR was consistently similar to mGFR in 
their associations with retinal vessel diameters. eGFRcrea was similar to mGFR in the main 
analyses, but this result was not stable when persons with low mGFR or eGFR were excluded 
in a sensitivity analysis. eGFRcys performed worse than eGFRcrea or eGFRcreacys in both the 
main and the sensitivity analysis.  
 
There have been several studies of non-GFR determinants of creatinine and cystatin C [1-4] 
which may explain the differences between mGFR and eGFR in the present study. However, 
we are not aware of any previous study where associations between pathological conditions 
and GFR estimates based on both markers have been compared with mGFR.  
 
To our knowledge, there are no previous cross-sectional studies of the relationship between 
retinal changes and the GFR in healthy persons from the general population. There are 
divergent results of investigations of the association between renal vessel diameters and 
chronic kidney disease (CKD) defined as eGFRcrea <60 mL/min/1.73 m2. Whereas some 
studies have found an association between narrow retinal arteries or wider retinal veins and 
the odds of having CKD, others have not [30,31].  
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The results of longitudinal studies of retinal vessel diameters as risk factors for incident CKD 
also differ. The Multi-Ethnic Study of Atherosclerosis (MESA) found an association between 
narrower retinal artery caliber and CKD in Caucasians but not in other races [32]. However, 
this finding was not reproduced in the Beaver Dam CKD Study [33]. Both studies used 
eGFRcrea. The Beaver Dam CKD Study also tested a criterion for CKD based on the cystatin 
C level, which gave the same result as eGFRcrea. The present study indicates there is no 
association between retinal vessel diameters and mGFR in the general population. The 
estimates of the three eGFR equations were all different from each other, which may partly 
explain the divergent results of previous studies (P<0.05)(Table 4). 
 
With regard to retinopathy, previous studies have found a positive relationship with CKD in 
non-diabetic persons [30,31,34,35]. Our results indicate that the cross-sectional association 
between reduced GFR and retinopathy extends into the normal GFR range and that it is 
independent of microalbuminuria (Table 3). This suggests that microvasculopathy may be the 
cause of the low mGFR of some of the subjects in the lowest quartile. Increasing age is 
associated with both retinal vascular damage and GFR decline, and mechanisms of aging 
could possibly be a common cause of both [8]. Although only mGFR was associated with 
retinopathy (P<0.05), none of the pairwise differences between mGFR and the three eGFRs 
were statistically significant when tested with seemingly unrelated regression methods. 
 
Retinopathy has been found to be a strong independent predictor of stroke [7], but the risk for 
stroke associated with an eGFRcrea in the low normal range has been found to be low and not 
statistically significant [36]. The attenuated odds ratios for retinopathy for eGFRcrea in the 
present study suggest that eGFRcrea may underestimate the risk for stroke relative to mGFR. 
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The attenuated odds ratios could be due to a low precision of eGFR or to the influence of non-
GFR factors.  
 
The different associations with retinal vessel diameters for eGFRcrea and eGFRcys were most 
likely due to the effects of non-GFR factors on cystatin C and creatinine. Although the 
differences were small, eGFR is typically used in large epidemiological studies where even 
small confounding effects may be significant. The difference of 8.1 µm between eGFRcrea and 
eGFRcys for the estimate of the central retinal vein diameter in the lowest quartile (Table 4) in 
this study corresponds to a hazard ratio of 1.2 for intracerebral hemorrhage for eGFRcys 
relative to eGFRcrea in the Rotterdam Study [6] and to 1.2 for lacunar stroke in the ARIC 
study [7].  
 
The most important strength of our study was that it used mGFR measured as iohexol 
clearance in a large population survey. Because the RENIS-T6-cohort is homogenous with 
respect to age, ethnicity and comorbidity and because we excluded persons with CKD, CVD 
or diabetes, the effects of non-GFR factors may be less than in many other studies. This 
strengthens the conclusion that there are important differences between eGFR based on only 
one endogenous substance and mGFR. Both the creatinine and cystatin C assays were 
calibrated to international standards, and we were able to adjust our analyses for most 
important confounders, including fasting glucose and albuminuria.  
 
One limitation of this investigation is that plasma iohexol clearance may slightly 
underestimate the gold-standard urinary inulin clearance [11]. To make GFR measurements in 
a large population survey possible, we chose to measure iohexol clearance with the single-
sample method. Although some studies have found differences between single-sample and 
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multiple-sample methods [37], other studies have found the methods similar [21,38-41].  It is 
unlikely that bias or imprecision of the GFR measurements relative to true GFR would be 
correlated with retinal changes. Accordingly, this would not be expected to influence our 
analyses, except possibly for an attenuation of estimates by regression dilution bias, which 
would not alter our conclusions. Another limitation of this investigation was that ethnicity 
was not investigated, as the RENIS-T6 included only persons of European ancestry. Also, 
because subjects with self-reported kidney disease were excluded, our results may not 
generalize to patients with chronic kidney disease. 
 
We conclude that the association of retinal changes with mGFR and eGFR based on cystatin 
C and/or creatinine differs even when other risk factors are adjusted for. The use of eGFR in 
studies of the relationship between the eye and the kidneys will give biased results relative to 
mGFR and may fail to detect important relationships as well as identifying spurious ones. The 
magnitude of bias when eGFR is used as a predictor of other outcomes should be assessed in 
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Fig. 1 Study population derived from the Renal Iohexol-Clearance Survey in Tromsø 6 
(RENIS-T6), which is an ancillary investigation of the sixth Tromsø Study. CKD indicates 









Table 1. Study population characteristics according to quartile of measured glomerular filtration rate. The RENIS-T6 Study.
Characteristic
Measured glomerular filtration rate,
 mL/min/1.73 m2 76.5 (70.5 to 80.0) 87.2 (84.9 to 89.4) 95.9 (93.7 to 98.3) 107.4 (103.7 to 113.5)
Female gender, % 69.6 55.2 48.6 31.7 <0.001
Age, years 60.5 (56.7 to 62.0) 59.2 (54.7 to 61.5) 57.8 (54.2 to 61.0) 57.1 (53.6 to 60.8) <0.001
Height, cm 169.1 (163.0 to 175.2) 169.7 (164.4 to 177.0) 169.7 (163.7 to 177.1) 173.0 (166.4 to 178.3) <0.001
Body weight, kg 77.5 (68.3 to 88.5) 77.6 (68.2 to 87.6) 77.9 (69.4 to 88.7) 81.3 (71.1 to 90.7) 0.04
Body mass index, kg/m2 26.7 (24.3 to 29.8) 26.6 (24.2 to 29.3) 26.9 (24.6 to 29.4) 27.0 (24.7 to 29.8) 0.71
First-degree relative with myocardial
 infarction before 60 years, % 23.2 16.0 20.6 19.6 <0.001
Current smoking, % 18.3 16.3 19.3 29.1 <0.001
10.4 11.5 12.1 11.8 0.05
Physical exercise*, % 50.5 60.7 59.5 52.2 0.99 ‡
Blood pressure
        Conventional
systolic, mmHg 128.0 (118.0 to 140.0) 129.0 (115.0 to 141.0) 127.0 (116.0 to 140.0) 127.0 (118.0 to 138.0) 0.83
diastolic, mmHg 83.0 (77.0 to 90.0) 83.0 (76.5 to 90.0) 83.0 (76.0 to 89.0) 83.0 (77.0 to 89.0) 0.85
        Daytime ambulatory
systolic, mmHg 128.0 (119.8 to 137.3) 128.5 (118.8 to 136.6) 128.7 (120.5 to 137.2) 132.1 (123.5 to 139.9) <0.001 ‡
diastolic, mmHg 80.2 (74.2 to 86.3) 81.5 (75.8 to 87.1) 81.8 (76.3 to 86.8) 83.3 (77.7 to 88.2) <0.001
mean arterial, mmHg 97.3 (90.5 to 103.6) 98.1 (90.9 to 103.9) 98.1 (91.6 to 103.9) 99.6 (93.8 to 105.4) <0.001
pulse pressure, mmHg 47.0 (42.2 to 53.1) 46.4 (41.7 to 51.6) 46.1 (42.0 to 51.9) 48.2 (43.2 to 53.0) 0.36 ‡
Hypertension†, % 43.8 42.8 41.9 37.9 0.14
Antihypertensive medication, % 21.1 17.0 16.7 14.9 0.02
Lipid-lowering medication, % 7.7 5.9 3.9 7.2 0.57
Non-steroidal antiinflammatory drugs, % 3.1 2.3 2.3 1.8 0.21
LDL-cholesterol, mmol/L 3.60 (3.00 to 4.20) 3.60 (3.10 to 4.20) 3.70 (3.20 to 4.30) 3.60 (3.10 to 4.20) 0.92
HDL-cholesterol, mmol/L 1.50 (1.30 to 1.90) 1.55 (1.30 to 1.80) 1.50 (1.20 to 1.80) 1.40 (1.20 to 1.70) <0.001
Triglycerides§, mmol/L 1.10 (0.80 to 1.50) 1.00 (0.70 to 1.30) 1.00 (0.70 to 1.50) 1.10 (0.70 to 1.50) 0.40 ‡
High-sensitivity C-reactive protein, mg/L 1.30 (0.67 to 2.36) 1.13 (0.62 to 2.13) 1.17 (0.63 to 2.18) 1.16 (0.65 to 2.05) 0.37
Fasting serum glucose, mmol/L 5.20 (4.90 to 5.50) 5.30 (5.00 to 5.50) 5.30 (5.00 to 5.60) 5.30 (5.10 to 5.80) <0.001
Urine albumin-creatinine ratio, mg/mmol 0.22 (0.10 to 0.53) 0.22 (0.10 to 0.50) 0.17 (0.10 to 0.46) 0.25 (0.10 to 0.54) 0.15
RENIS-T6 indicates the Renal Iohexol-clearance Survey in Tromsø 6.
Data are shown as median (interquartile range) or percent.
* Defined as leisuretime physical exercise leading to perspiration or breathlessness (yes/no).
† Defined as conventional systolic BP >140, conventional diastolic BP >90 or the use of antihypertensive medication.
‡ P<0.05 for quadratic trend.
§ Log-transformed when differences between quartiles were tested.
                mean no. of cigarettes 
smoked per day, if currently smoking
Quartile of measured glomerular filtration rate, range (mL/min/1.73 m2)




(21.9 to 82.8) (82.9 to 91.4) (91.4 to 100.9) (101.1 to 138.6)
25 
 
Central retinal artery equivalent, µm 140.5 (130.6 to 149.5) 139.7 (130.2 to 148.9) 140.2 (131.8 to 150.1) 140.9 (130.9 to 150.2) 0.36
Central retinal vein equivalent, µm 213.5 (199.5 to 227.6) 211.7 (196.1 to 224.5) 212.8 (197.5 to 226.0) 215.3 (200.3 to 226.6) 0.21
Microaneurysm count, N(%) 0.64
0 373 (96.0) 373 (96.0) 372 (95.7) 375 (96.8)
1 12 (3.2) 14 (3.7) 17 (4.3) 10 (2.4)
>1 3 (0.9) 1 (0.3) 0 (0.0) 3 (0.8)
Haemorrhage count, N(%) 0.14
0 340 (87.7) 360 (92.6) 352 (90.6) 353 (90.8)
1 41 (10.6) 25 (6.5) 35 (8.9) 29 (7.6)
>1 7 (1.7) 3 (0.8) 2 (0.6) 6 (1.6)
Cotton wool spot count, N(%) 0.92
0 387 (99.7) 387 (99.7) 389 (100.0) 387 (99.7)
>0 1 (0.3) 1 (0.3) 0 (0.0) 1 (0.3)
Retinopathy grade‡, N(%) 0.10
0 328 (84.5) 347 (89.5) 339 (87.1) 344 (88.6)
1 57 (14.6) 40 (10.2) 48 (12.3) 41 (10.5)
2 3 (0.9) 1 (0.3) 2 (0.6) 3 (0.8)
RENIS-T6 indicates the Renal Iohexol-clearance Survey in Tromsø 6. Data are shown as the median (interquartile range) or percent.
‡No subject had a retinopathy grade greater than 2.
§Quadratic trends across the quartiles were tested for all variables, but none were statistically significant (P≥0.05).
Table 2. Retinal photography data according to the quartile of measured glomerular filtration rate. The 
RENIS-T6 Study.
(21.9 to 82.8) (82.9 to 91.4) (91.4 to 100.9) (101.1 to 138.6)
Quartile of measured glomerular filtration rate, range (mL/min/1.73 m2)








Measured GFR 1.74 (1.10 to 2.75) 1.22 (0.76 to 1.96) 1.40 (0.89 to 2.19) 1.00 (Reference) 0.02 1.14 (1.02 to 1.28)
Estimated GFR
Creatinine 1.21 (0.75 to 1.94) 1.09 (0.67 to 1.77) 1.05 (0.66 to 1.68) 1.00 (Reference) 0.35 1.08 (0.92 to 1.28)
Cystatin C 1.20 (0.73 to 1.98) 1.16 (0.72 to 1.88) 1.09 (0.70 to 1.70) 1.00 (Reference) 0.25 1.08 (0.95 to 1.24)
Creatinine and cystatin C 1.53 (0.94 to 2.51) 1.35 (0.84 to 2.18) 1.34 (0.84 to 2.15) 1.00 (Reference) 0.19 1.10 (0.95 to 1.27)
Model 2
Measured GFR 1.86 (1.16 to 2.97) 1.30 (0.80 to 2.09) 1.48 (0.94 to 2.34) 1.00 (Reference) 0.01 1.16 (1.03 to 1.30)
Estimated GFR
Creatinine 1.26 (0.78 to 2.04) 1.13 (0.69 to 1.86) 1.06 (0.66 to 1.69) 1.00 (Reference) 0.24 1.11 (0.93 to 1.31)
Cystatin C 1.25 (0.74 to 2.11) 1.15 (0.70 to 1.87) 1.09 (0.70 to 1.71) 1.00 (Reference) 0.18 1.10 (0.95 to 1.28)
Creatinine and cystatin C 1.63 (0.98 to 2.70) 1.38 (0.85 to 2.24) 1.37 (0.85 to 2.21) 1.00 (Reference) 0.13 1.12 (0.97 to 1.30)
RENIS-T6 indicates the Renal Iohexol-clearance Survey in Tromsø 6; GFR glomerular filtration rate; mGFR measured GFR; eGFR estimated GFR; OR odds rato; CI confidence interva
*In both models, quadratic trends across the quartiles were tested for all mGFR and eGFR, but none were statistically significant (P≥0.05).
† In pairwise comparisons of the coefficients across the regression models with seemingly unrelated regression, none were statistically different  (P≥0.05).
Table 3. Multiple logistic regression analyses of associations between retinopathy and measured and estimated GFR. 
The RENIS-T6 Study.
Quartile of mGFR or eGFR
Model 1 was adjusted for age, sex, body weight, height, body mass index, antihypertenive medication, lipid-lowering drugs and non-steroidal antiinflammatory drugs. Model 2 was 
adjusted as model 1 and for first degree relative with myocardial infarction before 60 years of age, physical exercise, number of cigarettes currently smoked,  ambulatory daytime 
mean arterial pressure, ambulatory daytime pulse pressure, LDL-cholesterol, HDL_cholesterol, fasting triglycerides and serum high sensitivity C-reactive protein, urinary 
    
mGFR or eGFR as continuous 
independent variable†
OR per 10  mL/min/1.73 m2 
reduction (95% CI)OR for retinopathy grade > 0 (95% CI)







Central retinal artery equivalent, µm
Measured GFR 0.34
(-2.56 to 1.80) (-2.98 to 1.29) (-1.83 to 2.44) (-0.83 to 0.28)
Estimated GFR
Creatinine 0.08 0.22
(-4.31 to 0.24) (-3.65 to 1.00) (-1.89 to 2.48) (-1.56 to 0.09)
Cystatin C 0.01 <0.001 <0.001
(0.94 to 5.72) (-0.18 to 4.46) (-0.78 to 3.51) (0.23 to 1.60)
Creatinine and cystatin C 0.39 0.048 <0.001 0.001
(-2.00 to 2.63) (-0.55 to 3.90) (-1.60 to 2.67) (-0.40 to 1.02)
Central retinal vein equivalent, µm
Measured GFR 0.19
(-3.91 to 2.62) (-5.73 to 0.61) (-4.67 to 1.67) (-1.38 to 0.28)
Estimated GFR
Creatinine 0.08 0.30
(-7.25 to -0.45) (-5.36 to 1.54) (-3.59 to 2.95) (-2.37 to 0.12)
Cystatin C <0.001 <0.001 <0.001
(4.15 to 11.23) (0.95 to 7.94) (1.66 to 8.05) (1.30 to 3.32)
Creatinine and cystatin C 0.04 <0.001 <0.001 <0.001
(-0.92 to 5.92) (-0.22 to 6.41) (-1.39 to 4.93) (0.06 to 2.18)
Model 2
Central retinal artery equivalent, µm
Measured GFR 0.34
(-2.84 to 1.45) (-3.02 to 1.11) (-2.16 to 1.95) (-0.81 to 0.28)
Estimated GFR
Creatinine 0.17 0.41
(-3.84 to 0.61) (-3.04 to 1.40) (-1.61 to 2.54) (-1.38 to 0.25)
Cystatin C 0.047 0.004 0.003
(0.40 to 5.14) (-0.30 to 4.19) (-0.26 to 3.87) (0.01 to 1.37)
Creatinine and cystatin C 0.53 0.10 0.002 0.01
(-2.26 to 2.18) (-0.41 to 3.81) (-1.36 to 2.71) (-0.46 to 0.90)
Central retinal vein equivalent, µm
Measured GFR 0.21
(-4.31 to 2.41) (-5.28 to 1.17) (-4.76 to 1.57) (-1.41 to 0.31)
Estimated GFR
Creatinine 0.17 0.51
(-6.60 to 0.40) (-4.75 to 2.10) (-3.19 to 3.24) (-2.19 to 0.38)
Cystatin C 0.01 <0.001 0.001
(1.35 to 8.71) (-0.16 to 6.88) (1.21 to 7.59) (0.34 to 2.46)
Creatinine and cystatin C 0.28 0.01 <0.001 0.004




0.96 2.88 1.39 0.00
-0.91
(Reference)
5.03 3.36 4.40 0.00 1.40
RENIS-T6 indicates the Renal Iohexol-clearance Survey in Tromsø 6; GFR glomerular filtration rate; mGFR measured GFR; eGFR estimated GFR; CI confidence 
interval;  eGFRcrea, eGFRcys and eGFRcreacys GFR estimated from creatinine, cystatin C or both, respectively. Model 1 was adjusted for age, sex, body weight, 
height, body mass index, antihypertenive medication, lipid-lowering drugs and non-steroidal antiinflammatory drugs. Model 2 was adjusted as model 1 and for first 
degree relative with myocardial infarction before 60 years of age, physical exercise, number of cigarettes currently smoked,  ambulatory daytime mean arterial 
pressure, ambulatory daytime pulse pressure, LDL-cholesterol, HDL_cholesterol, fasting triglycerides and serum high sensitivity C-reactive protein, urinary 
albumin:creatinine-ratio and fasting serum glucose.
(Reference)
-3.10 -1.32 0.03 0.00
0.22
(Reference)
-0.95 -2.06 -1.59 0.00 -0.55
(Reference)
-0.04 1.70 0.67 0.00
-0.57
(Reference)
2.77 1.95 1.80 0.00 0.69
(Reference)
-1.61 -0.82 0.47 0.00
1.12
(Reference)
-0.69 -0.96 -0.11 0.00 -0.27
(Reference)
2.50 3.10 1.77 0.00
-1.13
(Reference)
7.69 4.45 4.85 0.00 2.31
(Reference)
-3.85 -1.91 -0.32 0.00
0.31
(Reference)
-0.65 -2.56 -1.50 0.00 -0.55
-0.27
(Reference)
0.31 1.68 0.53 0.00
-0.74
(Reference)
3.33 2.14 1.36 0.00 0.92
(Reference)
-2.03 -1.33 0.29 0.00










Table 4. Multiple linear regression analyses of associations between central retinal vessel equivalents and measured and estimated 
GFR. The RENIS-T6 Study.












P-values for statistical test 












Estimated and Measured GFR Associate Differently with Retinal 
Vasculopathy in the General Population 
Bjørn Odvar Eriksen MD PhD1,4,7, Maja-Lisa Løchen MD PhD2, Kjell Arne Arntzen MD3,5, Geir Bertelsen MD3,6, Britt-
Ann Winther Eilertsen RN7, Therese von Hanno MD3,9, Marit Herder MD2,8, Trond Geir Jenssen MD PhD1,10, Ulla Dorte 











Calibration of the baseline cystatin C measurements 
In 2013, 300 randomly selected baseline samples frozen at -80ºC were reanalyzed with the same 
cystatin C assay on a Cobas 8000 (Roche Diagnostics). The assay was calibrated with the Gentian 
calibrator (lot 1206401), which is fully traceable to the international reference ERM-DA471/IFCC [1]. 
Immediately before and after the series, an in-house control and an external control provided by 
Equalis were analyzed with identical results, which were identical to the established value for the in-
house control and 2.2% lower than the consensus value of the external control. The CV for the assay 
at the time of reanalysis was 2.9%. Using a Deming regression, the linear relationship between the 
two sets of measurements was found to be cystatin C2013= -0.064 + cystatin C2007 x 0.998. All the 





1 Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I: First certified reference material for 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mGFR eGFRcrea eGFRcy s
Model 1
Central retinal artery equivalent, µm
Measured GFR 0.45
(-3.10 to 1.29) (-2.85 to 1.51) (-1.96 to 2.34) (-0.86 to 0.38)
Estimated GFR
Creatinine 0.01 0.02
(-4.73 to -0.16) (-3.58 to 1.11) (-1.80 to 2.54) (-2.03 to -0.27)
Cystatin C 0.02 0.002 <0.001
(0.51 to 5.25) (-0.26 to 4.34) (-0.77 to 3.50) (0.14 to 1.59)
Creatinine and cystatin C 0.78 0.27 <0.001 <0.001
(-2.15 to 2.48) (-0.64 to 3.81) (-1.77 to 2.54) (-0.65 to 0.86)
Central retinal vein equivalent, µm
Measured GFR 0.37
(-4.15 to 2.44) (-5.68 to 0.79) (-4.37 to 2.02) (-1.35 to 0.50)
Estimated GFR
Creatinine 0.01 0.02
(-8.00 to -1.22) (-5.25 to 1.71) (-3.61 to 2.84) (-3.15 to -0.53)
Cystatin C <0.001 <0.001 <0.001
(3.80 to 10.89) (0.46 to 7.34) (2.01 to 8.40) (1.25 to 3.42)
Creatinine and cystatin C 0.13 0.01 <0.001 <0.001
(-1.32 to 5.63) (-0.14 to 6.49) (-1.84 to 4.64) (-0.27 to 1.99)
Model 2
Central retinal artery equivalent, µm
Measured GFR 0.32
(-3.38 to 0.86) (-2.88 to 1.32) (-2.34 to 1.79) (-0.91 to 0.30)
Estimated GFR
Creatinine 0.02 0.06
(-4.43 to -0.03) (-3.10 to 1.37) (-1.62 to 2.50) (-1.90 to -0.20)
Cystatin C 0.10 0.01 <0.001
(-0.03 to 4.69) (-0.56 to 3.92) (-0.24 to 3.89) (-0.12 to 1.33)
Creatinine and cystatin C 0.93 0.39 <0.001 0.001
(-2.56 to 1.92) (-0.67 to 3.59) (-1.54 to 2.58) (-0.76 to 0.70)
Central retinal vein equivalent, µm
Measured GFR 0.37
(-4.38 to 2.28) (-5.21 to 1.36) (-4.44 to 1.91) (-1.37 to 0.51)
Estimated GFR
Creatinine 0.02 0.04
(-7.33 to -0.55) (-4.73 to 2.16) (-3.24 to 3.10) (-2.92 to -0.29)
Cystatin C 0.02 0.002 <0.001
(1.20 to 8.48) (-0.61 to 6.27) (1.64 to 8.02) (0.24 to 2.51)
Creatinine and cystatin C 0.60 0.13 <0.001 <0.001
(-2.87 to 4.06) (-0.32 to 6.20) (-2.22 to 4.19) (-0.83 to 1.43)
* Subjects w ith mGFR, eGFRcrea, eGFRcys or eGFRcyscrea < 60 mL/min/1.73 m2 w ere excluded.
† P-values for pairw ise comparisons of the linear regression coeff icients across the regression models w ith seemingly unrelated regression.
(Reference)
RENIS-T6 indicates the Renal Iohexol-clearance Survey in Tromsø 6; GFR glomerular f iltration rate; mGFR measured GFR; eGFR estimated GFR; CI confidence interval;  eGFRcrea, eGFRcys and eGFRcreacys GFR estimated 
from creatinine, cystatin C or both, respectively. Model 1 w as adjusted for age, sex, body w eight, height, body mass index, antihypertenive medication, lipid-low ering drugs and non-steroidal antiinf lammatory drugs. Model 2 
w as adjusted as model 1 and for f irst degree relative w ith myocardial infarction before 60 years of age, physical exercise, number of cigarettes currently smoked,  ambulatory daytime mean arterial pressure, ambulatory 
daytime pulse pressure, LDL-cholesterol, HDL_cholesterol, fasting triglycerides and serum high sensitivity C-reactive protein, urinary albumin:creatinine-ratio and fasting serum glucose.
(Reference)
0.60 2.94 0.99 0.00 0.30
(Reference)
4.84 2.83 4.83 0.00 1.37
(Reference)
-3.94 -1.29 -0.07 0.00 -1.60
(Reference)
-1.05 -1.93 -1.27 0.00 -0.43
(Reference)
-0.32 1.46 0.52 0.00 -0.03
(Reference)
2.33 1.68 1.82 0.00 0.61
(Reference)
-2.23 -0.87 0.44 0.00 -1.05
(Reference)
-1.26 -0.78 -0.27 0.00 -0.30
(Reference)
2.16 3.18 1.40 0.00 0.86
(Reference)
7.35 3.90 5.21 0.00 2.33
(Reference)
-4.61 -1.77 -0.38 0.00 -1.84
(Reference)




10  mL/min/1.73 
m2 reduction 
(95% CI)
-0.90 -0.67 0.19 0.00 -0.24
(Reference)
0.16 1.58 0.39 0.00 0.11
(Reference)














-2.45 -1.24 0.37 0.00
Supplemental Table 3. Multiple linear regression analyses of associations between central retinal vessel equivalents and mGFR 
and eGFR  for subjects with mGFR and eGFR ≥ 60 mL/min/1.73 m2. The RENIS-T6 Study.*
Quartile of mGFR or eGFR
P-values for statistical test of 









Quartile 1 Quartile 2 Quartile 3 Quartile 4
 
 
 
